What happened
Mesoblast Limited (NASDAQ: MESO) said Ryoncil generated US$115.2 million in net product revenues in fiscal 2026. The annual report said this was its first full year of commercialization.
Total revenue reached US$120.3 million, up from US$17.2 million in fiscal 2025. Mesoblast also said it set up a US$125 million five-year non-dilutive credit facility.
Mesoblast said the pivotal Phase 3 CLBP trial completed treatment of 350 patients. It also said the adult SR-aGvHD registration trial is enrolling patients at multiple US sites.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Revenue | US$120.3 million | from US$17.2 million, +599.4% | Mesoblast annual report |
| Ryoncil net product revenues | US$115.2 million | Mesoblast annual report | |
| Net operating cash spend | US$43.8 million | from US$50.0 million, -12.4% | Mesoblast annual report |
| Cash reserves | US$102.9 million | Mesoblast annual report | |
| Credit facility | US$125 million | Mesoblast annual report | |
| Net loss | US$57.5 million | Mesoblast annual report |
Read more: Mesoblast (MESO) stock analysis and investment case
Why it matters
FY2026 revenue rose US$103.1 million from FY2025, a 599.4% increase. Ryoncil generated US$115.2 million of the US$120.3 million total, so it accounted for most reported sales.
The filing supports the commercialization story because Ryoncil produced its first full-year revenue and Mesoblast added financing capacity. The company said the credit facility is US$125 million, which gives it more room to fund commercialization and the pipeline.
The downside is that product revenue is still below operating expenses. Mesoblast reported a US$57.5 million net loss and US$1.07 billion in accumulated losses.
The company also said the CLBP program is a major commercial opportunity and that the trial treated 350 patients. That supports the pipeline case, but the filing still depends on later clinical results, not patient count alone.
Browse: stock research on every company OptimistFi covers
What's next
Mesoblast said it will report CLBP trial clinical endpoints in the second half of calendar 2027. That is the clearest dated test in the filing.
A positive readout would support the pipeline case. A weak result would shift attention back to Ryoncil sales and financing needs.
Mesoblast said fiscal 2027 priorities include maximizing RYONCIL availability, distribution and penetration in the pediatric market. It also said it will keep pursuing adult SR-aGvHD label expansion and advance rexlemestrocel-L.
More from OptimistFi
- MESO stock: the Mesoblast thesis, its status and the next test to watch
- Meta Platforms, Inc. (NASDAQ: META) Prices Muse Wonder for Developers
- American Superconductor Corporation (NASDAQ: AMSC) Revenue Rises as Margin Falls
- Levi Strauss & Co. (NYSE: LEVI) Raises Profit as Wholesale Outruns DTC
- Stock perps: $6.8 million evaporated on a single Cerebras long
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- Mesoblast Limited Form 6-K cover — SEC Form 6-K filed October 13, 2026
- Mesoblast annual report — Annual Report to Shareholders attached as Exhibit 99.1
Read the full OptimistFi thesis on Mesoblast Limited: https://optimistfi.com/stocks/MESO
See what would break the Mesoblast Limited thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Mesoblast Limited investment case, its status and the next test to watch live on the Mesoblast Limited thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
